{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:01:42Z","timestamp":1790665302358,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T00:00:00Z","timestamp":1491264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Breast Cancer Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Breast Cancer Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Breast Cancer Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Breast Cancer Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s10549-017-4225-5","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T06:29:15Z","timestamp":1491373755000},"page":"221-229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab"],"prefix":"10.1007","volume":"164","author":[{"given":"Andrew","family":"McGuire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kalinina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Holian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel A.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife","family":"Lowery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3155-0334","authenticated-orcid":false,"given":"James A. L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,4]]},"reference":[{"issue":"6797","key":"4225_CR1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747\u2013752","journal-title":"Nature"},{"issue":"8","key":"4225_CR2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A et al (2011) Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736\u20131747","journal-title":"Ann Oncol"},{"issue":"10","key":"4225_CR3","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MC Cheang","year":"2009","unstructured":"Cheang MC et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736\u2013750","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"4225_CR4","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ctrv.2011.11.005","volume":"38","author":"P Eroles","year":"2012","unstructured":"Eroles P et al (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 38(6):698\u2013707","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"4225_CR5","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/1055-9965.EPI-13-1023","volume":"23","author":"C Sweeney","year":"2014","unstructured":"Sweeney C et al (2014) Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomark Prev 23(5):714\u2013724","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"21","key":"4225_CR6","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492\u20132502","journal-title":"JAMA"},{"issue":"1\u20132","key":"4225_CR7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3121\/cmr.2008.825","volume":"7","author":"AA Onitilo","year":"2009","unstructured":"Onitilo AA et al (2009) Breast cancer subtypes based on ER\/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7(1\u20132):4\u201313","journal-title":"Clin Med Res"},{"issue":"20","key":"4225_CR8","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"H Kennecke","year":"2010","unstructured":"Kennecke H et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28(20):3271\u20133277","journal-title":"J Clin Oncol"},{"issue":"5","key":"4225_CR9","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/bcr3324","volume":"14","author":"I Vaz-Luis","year":"2012","unstructured":"Vaz-Luis I et al (2012) Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res 14(5):R129","journal-title":"Breast Cancer Res"},{"issue":"5","key":"4225_CR10","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1186\/bcr3559","volume":"15","author":"N Ribelles","year":"2013","unstructured":"Ribelles N et al (2013) Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res 15(5):R98","journal-title":"Breast Cancer Res"},{"issue":"10","key":"4225_CR11","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","volume":"28","author":"KD Voduc","year":"2010","unstructured":"Voduc KD et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684\u20131691","journal-title":"J Clin Oncol"},{"issue":"3","key":"4225_CR12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10549-011-1891-6","volume":"133","author":"AJ Lowery","year":"2011","unstructured":"Lowery AJ et al (2011) Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 133(3):831\u2013841","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4225_CR13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA (2007) Trastuzumab\u2013mechanism of action and use in clinical practice. N Engl J Med 357(1):39\u201351","journal-title":"N Engl J Med"},{"issue":"11","key":"4225_CR14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783\u2013792","journal-title":"N Engl J Med"},{"issue":"16","key":"4225_CR15","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673\u20131684","journal-title":"N Engl J Med"},{"issue":"25","key":"4225_CR16","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","volume":"29","author":"EA Perez","year":"2011","unstructured":"Perez EA et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29(25):3366\u20133373","journal-title":"J Clin Oncol"},{"issue":"16","key":"4225_CR17","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659\u20131672","journal-title":"N Engl J Med"},{"issue":"9555","key":"4225_CR18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","volume":"369","author":"I Smith","year":"2007","unstructured":"Smith I et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555):29\u201336","journal-title":"Lancet"},{"issue":"16","key":"4225_CR19","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","volume":"23","author":"AU Buzdar","year":"2005","unstructured":"Buzdar AU et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676\u20133685","journal-title":"J Clin Oncol"},{"issue":"9712","key":"4225_CR20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712):377\u2013384","journal-title":"Lancet"},{"key":"4225_CR21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-7-153","volume":"7","author":"GA Viani","year":"2007","unstructured":"Viani GA et al (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153","journal-title":"BMC Cancer"},{"key":"4225_CR22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13058-015-0648-2","volume":"17","author":"D Mendes","year":"2015","unstructured":"Mendes D et al (2015) The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer\u2013a systematic review. Breast Cancer Res 17:140","journal-title":"Breast Cancer Res"},{"issue":"9938","key":"4225_CR23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164\u2013172","journal-title":"Lancet"},{"issue":"20","key":"4225_CR24","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1002\/cncr.27502","volume":"118","author":"MM Kim","year":"2012","unstructured":"Kim MM et al (2012) Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer 118(20):4936\u20134943","journal-title":"Cancer"},{"issue":"11","key":"4225_CR25","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.2000.18.11.2349","volume":"18","author":"BC Pestalozzi","year":"2000","unstructured":"Pestalozzi BC, Brignoli S (2000) Trastuzumab in CSF. J Clin Oncol 18(11):2349\u20132351","journal-title":"J Clin Oncol"},{"issue":"3","key":"4225_CR26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1470-2045(13)70017-2","volume":"14","author":"BC Pestalozzi","year":"2013","unstructured":"Pestalozzi BC et al (2013) CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol 14(3):244\u2013248","journal-title":"Lancet Oncol"},{"issue":"5","key":"4225_CR27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jnci\/95.5.353","volume":"95","author":"CK Osborne","year":"2003","unstructured":"Osborne CK et al (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2\/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95(5):353\u2013361","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"4225_CR28","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1158\/1078-0432.CCR-04-2569","volume":"11","author":"M Laurentiis De","year":"2005","unstructured":"De Laurentiis M et al (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11(13):4741\u20134748","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4225_CR29","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djh166","volume":"96","author":"J Shou","year":"2004","unstructured":"Shou J et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer. J Natl Cancer Inst 96(12):926\u2013935","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"4225_CR30","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.3816\/CBC.2009.s.003","volume":"9","author":"SR Johnston","year":"2009","unstructured":"Johnston SR (2009) Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 9(Suppl 1):S28\u2013S36","journal-title":"Clin Breast Cancer"},{"issue":"20","key":"4225_CR31","first-page":"5887","volume":"60","author":"H Kurokawa","year":"2000","unstructured":"Kurokawa H et al (2000) Inhibition of HER2\/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60(20):5887\u20135894","journal-title":"Cancer Res"},{"issue":"25","key":"4225_CR32","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","volume":"29","author":"M Untch","year":"2011","unstructured":"Untch M et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29(25):3351\u20133357","journal-title":"J Clin Oncol"},{"issue":"1","key":"4225_CR33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25\u201332","journal-title":"Lancet Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-017-4225-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4225-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4225-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T10:08:03Z","timestamp":1497262083000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-017-4225-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,4]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["4225"],"URL":"https:\/\/doi.org\/10.1007\/s10549-017-4225-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,4]]}}}